Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Interest Expenses (2020 - 2021)

VYNE Therapeutics (VYNE) has disclosed Interest Expenses for 2 consecutive years, with $3.5 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Interest Expenses rose 218.13% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Jun 2022, down 20.85%, and an annual FY2021 reading of $5.6 million, up 27.79% over the prior year.
  • Interest Expenses was $3.5 million for Q3 2021 at VYNE Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.5 million in Q3 2021 and bottomed at $1.1 million in Q1 2021.